ISMRC 2023 Final Programme

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. From MRD and monitoring, to trials and therapy selection, we are leading the future. Join us as we redefine precision oncology. personalis.com Together, We Can Transform a Patient’s Cancer Journey. HAT OTHERS MISS